one question no ed.- Test Copy - 2024 - Essential Knowledge in the Clinical Use of Peptides Class

2024 Essential Knowledge in the Clinical Use of Peptides Class
Some questions have more than one correct answer, if you think a question meets this criteria, check two answer boxes for that question.

After you answer the last question, please be patient while your test is being graded it may take up to 1 minute before you know your results.

Clinical Peptide Society

Please enter the information below.

1 / 3

1. What is the most common receptor for peptides?

a. Tyrosine kinase receptor

b. Ion channel receptor

c. G Protein coupled receptor

d. All of the above

2 / 3

2. What is true for Vasoactive Intestinal Peptide (VIP)

a. VIP levels are lower in ulcerative colitis patients compared to a healthy control

b. In an animal study VIP treatment helped in mice model with Crohn’s disease

c. Patients with lower VIP levels in Spondyloarthritis have more swelling and disability compared to a healthy control

d. In animal studies VIP has shown to reduce inflammation in osteoarthritis and with rheumatoid arthritis

e. All of the above

3 / 3

3. An acceptable dosing of MOTS-c is

a. 10 mg SQ once a week

a. 5 mg SQ two times a week

b. 100 mg SQ once a week

d. 50 mg SQ 2 times a week

e. A and B

f. C and D

Your score is

0%

Q2-One

Clinical Peptide Society